S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent

Revolution Medicines (RVMD) Stock Price, News & Analysis

$32.23
+0.51 (+1.61%)
(As of 03/28/2024 ET)
Today's Range
$31.33
$32.48
50-Day Range
$26.56
$33.55
52-Week Range
$15.44
$35.60
Volume
997,438 shs
Average Volume
1.37 million shs
Market Capitalization
$5.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.80

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.4% Upside
$38.80 Price Target
Short Interest
Bearish
9.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.57mentions of Revolution Medicines in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$422,220 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.17) to ($3.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

478th out of 938 stocks

Biological Products, Except Diagnostic Industry

77th out of 149 stocks

RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
RVMD Apr 2024 36.000 call
RVMD Apr 2024 33.000 put
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
RVMD Sep 2024 21.000 put
RVMD Mar 2024 33.000 put
RVMD Mar 2024 36.000 call
RVMD Apr 2024 21.000 put
RVMD Apr 2024 21.000 call
Revolution Medicines Inc. (US76155X1000.SG)
RVMD Apr 2024 31.000 put
Revolution Medicines, Inc. (RVMD)
Q4 2023 Revolution Medicines Inc Earnings Call
TD Cowen Sticks to Their Buy Rating for Revolution Medicines (RVMD)
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
378
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.80
High Stock Price Target
$47.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+20.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-436,370,000.00
Net Margins
-1,003.36%
Pretax Margin
-3,798.71%

Debt

Sales & Book Value

Annual Sales
$11.58 million
Book Value
$11.09 per share

Miscellaneous

Free Float
150,691,000
Market Cap
$5.31 billion
Optionable
Optionable
Beta
1.53
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

10 brokers have issued 12 month price objectives for Revolution Medicines' shares. Their RVMD share price targets range from $28.00 to $47.00. On average, they predict the company's stock price to reach $38.80 in the next year. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD shares have increased by 12.4% and is now trading at $32.23.
View the best growth stocks for 2024 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings results on Monday, February, 26th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.29. The company earned $0.74 million during the quarter, compared to analysts' expectations of $1.20 million. Revolution Medicines had a negative trailing twelve-month return on equity of 38.39% and a negative net margin of 1,003.36%. Revolution Medicines's quarterly revenue was down 95.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.63) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.04%), Vanguard Group Inc. (13.36%), Vanguard Group Inc. (8.89%), Nextech Invest Ltd. (5.75%), BVF Inc. IL (5.46%) and Bellevue Group AG (4.65%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners